Sana Biotechnology, Inc. (SANA)
Sana Biotechnology develops engineered cell therapies for type 1 diabetes and B cell diseases, based in Seattle. It last closed at $1.88 on Nov 17, up 0.00% on the day. The average 12-month price target from 2 analysts is $12.00 (+538.3% from the last close), with a high of $13.00 and a low of $11.00. In the past 30 days there were 1 dark pool print totaling $120K, the largest $120K.
Key Stats
Last 12 monthsNot reported for this period.
From SANA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on SANA in the past 90 days. The average target is $12.00, with a high of $13.00 and a low of $11.00, compared with the last close of $1.88.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Citigroup | Maintained | Buy | $11 |
| Nov 16 | Morgan Stanley | Maintained | Buy | $13 |
| Aug 14 | B of A Securities | Maintained | Buy | $6 |
Technical Analysis
The stock is 25% below its 20 day and 41% below its 50 day average. It is 73% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $1.84, and the nearest resistance the Pivot R1 at $1.91.
| RSI (14) | 29.87 | Oversold below 30 | Oversold |
| MACD | -0.19 | Below its signal line | Bearish |
| Stochastic | 7.5 | Near the bottom of its range | Oversold |
| ADX (14) | 26.2 | Trending down | |
| Williams %R | -96.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -200.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −22.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.18 | Typical daily range, 9.6% of price |
| RSI (14) | 33.13 | Weak, oversold below 30 | Neutral |
| MACD | -0.36 | Below its signal line | Bearish |
| Stochastic | 5.2 | Near the bottom of its range | Oversold |
| ADX (14) | 12.8 | No clear trend | |
| Williams %R | -98.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -153.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −39.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.48 | Typical daily range, 25.4% of price |
What happened before
See how SANA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SANA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in SANA in the last 90 days.
Dark Pool
30DSANA Institutional Ownership
Full report →- ▼79 buying vs 101 selling
- ▲Held by funds +14.9 pts
- ▼Funds holding -9
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 202 | 211 | −4.3% |
| In funds' top 10 | 4 | 3 | +33.3% |
| Held by funds | 76.6% | 61.7% | +14.9 pts |
| New / increased | 23 / 56 | 31 / 68 | −20.2% |
| Reduced / sold out | 71 / 30 | 61 / 23 | +20.2% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SANA is in one of them and how their past SANA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SANA in an article yet. Here's the latest on the wider market.
About Sana Biotechnology
Sana Biotechnology is a biotechnology company based in Seattle, Washington, that develops engineered cell therapies. Its lead candidate, SC451, is meant to treat type 1 diabetes with cells that can be transplanted without immunosuppression. Its in vivo CAR T candidate, SG293, is being developed for B cell cancers and B cell mediated autoimmune diseases. The company's products are still in development and are aimed at patients with these conditions.
- Headquarters
- Seattle, WA
- Website
- sana.com ↗



